Clinical significance of dihydropyrimidine dehydrogenase and thymidylate synthase expression in patients with pancreatic cancer

Abstract

The efficacy of 5-FU may be lower in pancreatic cancer tissue than in normal tissue because DPD activity is upregulated in pancreatic cancer tissue compared to normal pancreatic tissue. It is necessary to develop an effective 5-FU delivery system and/or 5-FU combined with an inhibitor for DPD that can be used when 5-FU must be administered to patients with pancreatic cancer. High DPD activity may be a prognostic factor in patients with pancreatic cancer.

Glycogen synthase kinase 3β inhibition sensitizes pancreatic cancer cells to gemcitabine

“…Therefore, inhibition of GSK3b may sensitize pancreatic cancer cells to gemcitabine via sequential modification of the Rb/E2F pathway. It was recently reported that TS, a target of E2F transcription and fluoropyrimidine-derived chemotherapeutic agents, is frequently activated in primary pancreatic cancer tissues [46]. This suggests that inhibition of GSK3b also sensitizes pancreatic cancer cells to fluoropyrimidines, such as 5-fluorouracil and S-1, which are prescribed for patients with advanced and/or recurrent pancreatic cancer.…”

Prognostic significance of thymidylate synthase expression in pancreatic adenocarcinoma: A meta-analysis

“…The characteristics of the eligible studies are summarized in Table I. A total of 5 studies (9)(10)(11)13,19), published between 2002 and 2012, met the inclusion criteria for this review. A total of 425 patients were subjected to the final analysis.…”

“…However, conflicting results have been reported from various laboratories. Besides its predictive value, the reported findings on the expression levels and prognostic value of TS are also inconsistent (9)(10)(11)(12)(13). Therefore, a meta-analysis was performed to assess the prognostic value of TS protein expression for the survival of patients with pancreatic adenocarcinoma.…”

Prognostic Value of Excision Repair Cross-Complementing Gene 1, Dihydropyrimidine Dehydrogenase, and Human Equilibrative Nucleotide Transporter 1 Expression and Their Implications for Adjuvant Treatment in Patients With Ampullary Carcinoma

“…Although conflicting results have been reported, [19][20][21][22] Tsuji et al 10 reported that DPD low was significantly associated with reduced RFS in stage II to stage III colorectal cancers treated with surgery alone.…”